Seeking Alpha

BG Medicine (BGMD) rockets 24% after saying it has received the EU's CE mark for the first...

BG Medicine (BGMD) rockets 24% after saying it has received the EU's CE mark for the first automated version of the company's Galectin-3 blood test for improving the management of heart conditions. BG is working with four partners to commercialize the test, including Abbott Labs (ABT) and Siemens (SI). The EU approval comes just a week after SA author Robert Fabian called BG Medicine a "hidden gem." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector